| Rise of Deep Learning for Genomic, Proteomic, and Metabolomic Data Integration in Precision Medicine |
24 |
| Birth of Industry 5.0: Making Sense of Big Data with Artificial Intelligence, The Internet of Things and Next-Generation Technology Policy |
24 |
| Quantitative Assessment of Shotgun Metagenomics and 16S rDNA Amplicon Sequencing in the Study of Human Gut Microbiome |
16 |
| The Gut Microbiome and Mental Health: Implications for Anxiety- and Trauma-Related Disorders |
14 |
| Not Everyone Fits the Mold: Intratumor and Intertumor Heterogeneity and Innovative Cancer Drug Design and Development |
14 |
| Atorvastatin Treatment Modulates the Gut Microbiota of the Hypercholesterolemic Patients |
9 |
| Rethinking Drug Repositioning and Development with Artificial Intelligence, Machine Learning, and Omics |
9 |
| Innovating Governance for Planetary Health with Three Critically Informed Frames |
9 |
| Bovine Milk Comparative Proteome Analysis from Early, Mid, and Late Lactation in the Cattle Breed, Malnad Gidda (Bos indicus) |
8 |
| Interethnic Variability in CYP2D CYP2C and CYP2C19 Genes and Predicted Drug Metabolism Phenotypes Among 6060 Ibero- and Native Americans: RIBEF-CEIBA Consortium Report on Population Pharmacogenomics |
8 |
| New Insights on Obesity and Diabetes from Gut Microbiome Alterations in Egyptian Adults |
8 |
| Epigenomics-Guided Drug Development: Recent Advances in Solving the Cancer Treatment jigsaw puzzle |
7 |
| Genomics and Epigenomics of Congenital Heart Defects: Expert Review and Lessons Learned in Africa |
7 |
| Three-Dimensional Organoids in Cancer Research: The Search for the Holy Grail of Preclinical Cancer Modeling |
6 |
| Systematic Review: Immunoglobulin G N-Glycans as Next-Generation Diagnostic Biomarkers for Common Chronic Diseases |
6 |
| Meta-microRNA Biomarker Signatures to Classify Breast Cancer Subtypes |
6 |
| Targeting the Versatile Wnt/beta-Catenin Pathway in Cancer Biology and Therapeutics: From Concept to Actionable Strategy |
6 |
| Effect of Sweetened Dried Cranberry Consumption on Urinary Proteome and Fecal Microbiome in Healthy Human Subjects |
6 |
| What does Diversity Mean for Public Engagement in Science? A New Metric for Innovation Ecosystem Diversity |
6 |
| The Dark Side of the Moon: The Internet of Things, Industry 4. and The Quantified Planet |
6 |
| Personalized Herbal Medicine? A Roadmap for Convergence of Herbal and Precision Medicine Biomarker Innovations |
6 |
| Drug Targeting and Biomarkers in Head and Neck Cancers: Insights from Systems Biology Analyses |
5 |
| Systematic Review: Clinical Metabolomics to Forecast Outcomes in Liver Transplantation Surgery |
5 |
| Sarcoidosis Related Novel Candidate Genes Identified by Multi-Omics Integrative Analyses |
5 |
| Unlocking Human Brain Metabolism by Genome-Scale and Multiomics Metabolic Models: Relevance for Neurology Research, Health, and Disease |
5 |
| A Systems Biology Approach to Understanding the Pathophysiology of High-Grade Serous Ovarian Cancer: Focus on Iron and Fatty Acid Metabolism |
5 |
| Rise of Systems Glycobiology and Personalized Glycomedicine: Why and How to Integrate Glycomics with Multiomics Science? |
5 |
| Novel Genomic Biomarker Candidates for Cervical Cancer As Identified by Differential Co-Expression Network Analysis |
4 |
| Next-Generation Metagenomics: Methodological Challenges and Opportunities |
4 |
| Toward Precision Nutrition: Commercial Infant Formulas and Human Milk Compared for Stereospecific Distribution of Fatty Acids Using Metabolomics |
4 |
| Culturomics: A New Kid on the Block of OMICS to Enable Personalized Medicine |
4 |
| The Big Picture on the AI Turn for Digital Health: The Internet of Things and Cyber-Physical Systems |
4 |
| From Genomics to Omics Landscapes of Parkinson's Disease: Revealing the Molecular Mechanisms |
4 |
| Multi-Omics for Biomarker Discovery and Target Validation in Biofluids for Amyotrophic Lateral Sclerosis Diagnosis |
4 |
| Toward the Drug Factory Microbiome: Microbial Community Variations in Antibiotic-Producing Clean Rooms |
3 |
| MicroRNA Mediated Changes in Drug Metabolism and Target Gene Expression by Efavirenz and Rifampicin In Vitro: Clinical Implications |
3 |
| Rebooting Bioresilience: A Multi-OMICS Approach to Tackle Global Catastrophic Biological Risks and Next-Generation Biothreats |
3 |
| Mapping Keratoconus Molecular Substrates by Multiplexed High-Resolution Proteomics of Unpooled Corneas |
3 |
| IMass Time: The Future, in Future! |
3 |
| The Genetics of Warfarin Dose-Response Variability in Africans: An Expert Perspective on Past, Present, and Future |
3 |
| Biomolecular Databases and Subnetwork Identification Approaches of Interest to Big Data Community: An Expert Review |
3 |
| Panvigilance: Integrating Biomarkers in Clinical Trials for Systems Pharmacovigilance |
3 |
| Genetics of Obstructive Sleep Apnea: Vitamin D Receptor Gene Variation Affects Both Vitamin D Serum Concentration and Disease Susceptibility |
3 |
| Skin Microbiome Differences in Atopic Dermatitis and Healthy Controls in Egyptian Children and Adults, and Association with Serum Immunoglobulin E |
3 |
| Time-Dependent Changes in Urinary Metabolome Before and After Intensive Phase Tuberculosis Therapy: A Pharmacometabolomics Study |
3 |
| Humanome Versus Microbiome: Games of Dominance and Pan-Biosurveillance in the Omics Universe |
3 |
| Human Optic Nerve: An Enhanced Proteomic Expression Profile |
3 |
| Novel Epigenomic Biomarkers of Male Infertility Identified by Methylation Patterns of CpG Sites Within Imprinting Control Regions of H19 and SNRPN Genes |
3 |
| Metabolomics-Based Biosignatures of Prostate Cancer in Patients Following Radiotherapy |
3 |
| Analyses of Livestock-Associated Staphylococcus aureus Pan-Genomes Suggest Virulence Is Not Primary Interest in Evolution of Its Genome |
3 |
